A case of chemotherapy-induced menopause left unmanaged for six years prompted a physician’s pointed critique of survivorship care failures, highlighting the clinical and legal stakes of untreated premature ovarian insufficiency following gonadotoxic therapy.

ACOG released its first maternal immunization schedule formally diverging from federal vaccine recommendations, following its February 2026 withdrawal from the CDC Advisory Committee on Immunization Practices over concerns about the committee’s scientific integrity.

More than half of women aged 50–80 reported sleep problems in a cross-sectional survey analysis, with symptomatic menopausal women significantly more likely to be affected than those without menopausal symptoms.

The American Thyroid Association released updated evidence-based recommendations for thyroid disease in preconception, pregnancy, and postpartum, incorporating new trial data on LT4 treatment thresholds, TPOAb management, and ATD safety that diverge meaningfully from 2017 guidance.

Nearly 18 million US women aged 45–64 were overdue for at least one recommended breast, cervical, or colorectal cancer screening, with colorectal cancer representing the largest unmet need in a 2024 BRFSS analysis of 36.2 million women.

A network meta-analysis of 716 randomized trials and 159,362 participants found ARB-based regimens had the lowest rates of treatment discontinuation due to adverse effects, with the ARB-CCB combination ranking as the best-tolerated dual-drug option among antihypertensive regimens examined.